Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Arcus Biosciences, Inc. or Beam Therapeutics Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Arcus Biosciences, Inc. and Beam Therapeutics Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Arcus Biosciences, Inc. and Beam Therapeutics Inc.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Latest Biotechnology and Arcus Biosciences, Inc., Beam Therapeutics Inc. Stock News

As of September 2, 2026, Arcus Biosciences, Inc. had a $3.8 billion market capitalization, compared to the Biotechnology median of $288.9 million. Arcus Biosciences, Inc.’s stock is up 23% in 2026, down 4.2% in the previous five trading days and up 176.13% in the past year.

Currently, Arcus Biosciences, Inc. does not have a price-earnings ratio. Arcus Biosciences, Inc.’s trailing 12-month revenue is $117.0 million with a -393.2% net profit margin. Year-over-year quarterly sales growth most recently was -74.4%. Analysts expect adjusted earnings to reach $-3.526 per share for the current fiscal year. Arcus Biosciences, Inc. does not currently pay a dividend.

As of September 2, 2026, Beam Therapeutics Inc. had a $2.9 billion market cap, putting it in the 59th percentile of all stocks. Beam Therapeutics Inc.’s stock is up 3.3% in 2026, down 6.1% in the previous five trading days and up 79.58% in the past year.

Currently, Beam Therapeutics Inc. does not have a price-earnings ratio. Beam Therapeutics Inc.’s trailing 12-month revenue is $156.0 million with a -55.4% net profit margin. Year-over-year quarterly sales growth most recently was -94.1%. Analysts expect adjusted earnings to reach $-4.454 per share for the current fiscal year. Beam Therapeutics Inc. does not currently pay a dividend.

How We Compare Arcus Biosciences, Inc. and Beam Therapeutics Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Arcus Biosciences, Inc. and Beam Therapeutics Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Arcus Biosciences, Inc. and Beam Therapeutics Inc. Stock Value Grades

Company	Ticker	Value
Arcus Biosciences, Inc.	RCUS	F
Beam Therapeutics Inc.	BEAM	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Arcus Biosciences, Inc. has a Value Score of 3, which is Ultra Expensive. Beam Therapeutics Inc. has a Value Score of 14, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Arcus Biosciences, Inc. or Beam Therapeutics Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Arcus Biosciences, Inc. or Beam Therapeutics Inc. is the better investment when it comes to value.

Arcus Biosciences, Inc. and Beam Therapeutics Inc. Growth Grades

Company	Ticker	Growth
Arcus Biosciences, Inc.	RCUS	F
Beam Therapeutics Inc.	BEAM	na

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Arcus Biosciences, Inc. has a Growth Score of 12, which is Very Weak. Beam Therapeutics Inc. does not have a meaningful Growth Score.

The Growth Stock Winner: No Clear Winner

Neither Arcus Biosciences, Inc. or Beam Therapeutics Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Arcus Biosciences, Inc. or Beam Therapeutics Inc. is the better investment when it comes to sustainable growth.

Arcus Biosciences, Inc. and Beam Therapeutics Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Arcus Biosciences, Inc.	RCUS	D
Beam Therapeutics Inc.	BEAM	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Arcus Biosciences, Inc. has a Earnings Estimate Score of 29, which is Negative. Beam Therapeutics Inc. has a Earnings Estimate Score of 34, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Arcus Biosciences, Inc. or Beam Therapeutics Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Arcus Biosciences, Inc. or Beam Therapeutics Inc. is the better investment when it comes to estimate revisions.

Other Arcus Biosciences, Inc. and Beam Therapeutics Inc. Grades

In addition to Growth, Value and Estimate Revisions, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Arcus Biosciences, Inc. and Beam Therapeutics Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Arcus Biosciences, Inc. or Beam Therapeutics Inc. Stock?

Overall, Arcus Biosciences, Inc. stock has a Value Score of 3, Growth Score of 12 and Estimate Revisions Score of 29.

Beam Therapeutics Inc. stock has a Value Score of 14, Growth Score of and Estimate Revisions Score of 34.

Comparing Arcus Biosciences, Inc. and Beam Therapeutics Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.